Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 58

1.

Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer.

Rao SS, Stoehr J, Dokic D, Wan L, Decker JT, Konopka K, Thomas AL, Wu J, Kaklamani VG, Shea LD, Jeruss JS.

Oncotarget. 2017 Aug 10;8(48):83925-83939. doi: 10.18632/oncotarget.20202. eCollection 2017 Oct 13.

2.

Molecular Subtypes and Local-Regional Control of Breast Cancer.

Fragomeni SM, Sciallis A, Jeruss JS.

Surg Oncol Clin N Am. 2018 Jan;27(1):95-120. doi: 10.1016/j.soc.2017.08.005. Review.

PMID:
29132568
3.

Embryonic Stem Cell Secreted Factors Decrease Invasiveness of Triple-Negative Breast Cancer Cells Through Regulome Modulation.

Tarasewicz E, Oakes RS, Aviles MO, Straehla J, Chilton KM, Decker JT, Wu J, Shea LD, Jeruss JS.

Cancer Biol Ther. 2017 Oct 20:0. doi: 10.1080/15384047.2017.1385681. [Epub ahead of print]

PMID:
29053396
4.

New Persistent Opioid Use Among Patients With Cancer After Curative-Intent Surgery.

Lee JS, Hu HM, Edelman AL, Brummett CM, Englesbe MJ, Waljee JF, Smerage JB, Griggs JJ, Nathan H, Jeruss JS, Dossett LA.

J Clin Oncol. 2017 Dec 20;35(36):4042-4049. doi: 10.1200/JCO.2017.74.1363. Epub 2017 Oct 19.

PMID:
29048972
5.

Engineering the pre-metastatic niche.

Aguado BA, Bushnell GG, Rao SS, Jeruss JS, Shea LD.

Nat Biomed Eng. 2017;1. pii: 0077. doi: 10.1038/s41551-017-0077. Epub 2017 Jun 13.

6.

Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells.

Thomas AL, Lind H, Hong A, Dokic D, Oppat K, Rosenthal E, Guo A, Thomas A, Hamden R, Jeruss JS.

Cell Cycle. 2017 Aug 3;16(15):1453-1464. doi: 10.1080/15384101.2017.1338988. Epub 2017 Jul 5.

PMID:
28678584
7.

Systems analysis of dynamic transcription factor activity identifies targets for treatment in Olaparib resistant cancer cells.

Decker JT, Hobson EC, Zhang Y, Shin S, Thomas AL, Jeruss JS, Arnold KB, Shea LD.

Biotechnol Bioeng. 2017 Sep;114(9):2085-2095. doi: 10.1002/bit.26293. Epub 2017 May 18.

PMID:
28322442
8.

Oncofertility program implementation increases access to fertility preservation options and assisted reproductive procedures for breast cancer patients.

Vu JV, Llarena NC, Estevez SL, Moravek MB, Jeruss JS.

J Surg Oncol. 2017 Feb;115(2):116-121. doi: 10.1002/jso.24418. Epub 2016 Dec 14.

9.

Enhanced Survival with Implantable Scaffolds That Capture Metastatic Breast Cancer Cells In Vivo.

Rao SS, Bushnell GG, Azarin SM, Spicer G, Aguado BA, Stoehr JR, Jiang EJ, Backman V, Shea LD, Jeruss JS.

Cancer Res. 2016 Sep 15;76(18):5209-18. doi: 10.1158/0008-5472.CAN-15-2106.

10.

Primordial Follicle Transplantation within Designer Biomaterial Grafts Produce Live Births in a Mouse Infertility Model.

Kniazeva E, Hardy AN, Boukaidi SA, Woodruff TK, Jeruss JS, Shea LD.

Sci Rep. 2015 Dec 3;5:17709. doi: 10.1038/srep17709.

11.

In vivo capture and label-free detection of early metastatic cells.

Azarin SM, Yi J, Gower RM, Aguado BA, Sullivan ME, Goodman AG, Jiang EJ, Rao SS, Ren Y, Tucker SL, Backman V, Jeruss JS, Shea LD.

Nat Commun. 2015 Sep 8;6:8094. doi: 10.1038/ncomms9094.

12.

Impact of Fertility Concerns on Tamoxifen Initiation and Persistence.

Llarena NC, Estevez SL, Tucker SL, Jeruss JS.

J Natl Cancer Inst. 2015 Aug 25;107(10). pii: djv202. doi: 10.1093/jnci/djv202. Print 2015 Oct.

PMID:
26307641
13.

Understanding Fertility in Young Female Cancer Patients.

Waimey KE, Smith BM, Confino R, Jeruss JS, Pavone ME.

J Womens Health (Larchmt). 2015 Oct;24(10):812-8. doi: 10.1089/jwh.2015.5194. Epub 2015 Jun 15. Review.

14.

Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).

Kaklamani VG, Jeruss JS, Hughes E, Siziopikou K, Timms KM, Gutin A, Abkevich V, Sangale Z, Solimeno C, Brown KL, Jones J, Hartman AR, Meservey C, Jovanovic B, Helenowski I, Khan SA, Bethke K, Hansen N, Uthe R, Giordano S, Rosen S, Hoskins K, Von Roenn J, Jain S, Parini V, Gradishar W.

Breast Cancer Res Treat. 2015 Jun;151(3):629-38. doi: 10.1007/s10549-015-3435-y. Epub 2015 May 26.

PMID:
26006067
15.

Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells.

Tarasewicz E, Rivas L, Hamdan R, Dokic D, Parimi V, Bernabe BP, Thomas A, Shea LD, Jeruss JS.

Cell Cycle. 2014;13(20):3191-201. doi: 10.4161/15384101.2014.950126.

16.

Dynamic transcription factor activity and networks during ErbB2 breast oncogenesis and targeted therapy.

Weiss MS, Peñalver Bernabé B, Shin S, Asztalos S, Dubbury SJ, Mui MD, Bellis AD, Bluver D, Tonetti DA, Saez-Rodriguez J, Broadbelt LJ, Jeruss JS, Shea LD.

Integr Biol (Camb). 2014 Dec;6(12):1170-82. doi: 10.1039/c4ib00086b.

17.

A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.

Lee O, Page K, Ivancic D, Helenowski I, Parini V, Sullivan ME, Margenthaler JA, Chatterton RT Jr, Jovanovic B, Dunn BK, Heckman-Stoddard BM, Foster K, Muzzio M, Shklovskaya J, Skripkauskas S, Kulesza P, Green D, Hansen NM, Bethke KP, Jeruss JS, Bergan R, Khan SA.

Clin Cancer Res. 2014 Jul 15;20(14):3672-82. doi: 10.1158/1078-0432.CCR-13-3045.

18.

CDK4 inhibition and doxorubicin mediate breast cancer cell apoptosis through Smad3 and survivin.

Tarasewicz E, Hamdan R, Straehla J, Hardy A, Nunez O, Zelivianski S, Dokic D, Jeruss JS.

Cancer Biol Ther. 2014 Oct;15(10):1301-11. doi: 10.4161/cbt.29693. Epub 2014 Jul 9.

19.

Risk factors for unplanned readmissions following excisional breast surgery.

Khavanin N, Bethke KP, Lovecchio FC, Jeruss JS, Hansen NM, Kim JY.

Breast J. 2014 May-Jun;20(3):288-94. doi: 10.1111/tbj.12253. Epub 2014 Apr 2.

PMID:
24689860
20.

Abstract 46: The BRA Score: Creating a General Risk Calculator for Breast Reconstruction Outcomes.

Khavanin N, Kim JY, Davila AA, Ver Halen JP, Mlodinow AS, Bethke KP, Khan SA, Jeruss JS, Hansen NM, Bilimoria KY, Losken A, Fine NA.

Plast Reconstr Surg. 2014 Mar;133(3 Suppl):56-7. doi: 10.1097/01.prs.0000445079.93837.65. No abstract available.

PMID:
25942157

Supplemental Content

Loading ...
Support Center